Summary & Overview
HCPCS Q2039: Influenza Virus Vaccine, Not Otherwise Specified
HCPCS Level II code Q2039 denotes an influenza virus vaccine coded as "not otherwise specified." Nationally, this code captures administrations of influenza vaccine products that lack a more specific HCPCS identifier, supporting billing and tracking for seasonal immunization efforts across outpatient and community settings. The code is relevant to payers managing preventive care benefits and vaccine program logistics.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose and service settings, plus practical context for claims processing and payer coverage considerations. The content highlights what stakeholders need to know about where the code is typically used, which payers commonly reimburse it, and what to expect in terms of administrative classification.
This publication provides benchmarks and policy context where available, describes typical service lines and sites of service for influenza vaccination, and notes when Q2039 is used versus more specific vaccine codes. Data limitations are clearly identified where input details are not provided.
Billing Code Overview
HCPCS Level II code Q2039 represents an influenza virus vaccine, not otherwise specified. This code is used to report administration of an influenza vaccine formulation when a more specific vaccine code is not applicable or the product is not otherwise identified by a more precise HCPCS code.
Service Type: Vaccine administration / Immunization service
Typical Site of Service: Outpatient clinics, physician offices, pharmacies, public health clinics, and other outpatient immunization settings
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric clinic patient presenting for routine seasonal influenza vaccination. The patient may be healthy or have chronic medical conditions (eg, asthma, diabetes, chronic heart disease) that increase influenza risk. The clinical workflow: registration and verification of insurance and immunization history; screening for contraindications (egg allergy, Guillain-Barré history, acute febrile illness); counseling on vaccine benefits and risks; obtaining informed consent; administration of the influenza vaccine using Q2039 (influenza virus vaccine, not otherwise specified) via intramuscular injection; documentation of lot number, manufacturer, expiration date, anatomical site, and VIS (Vaccine Information Statement) date; observation for immediate adverse reaction (15 minutes, or 30 minutes for history of severe allergic reaction); billing and submission to the patient’s payor. Typical sites of service include ambulatory clinic, physician office, community health center, pharmacy-based clinic, and public health vaccination events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — not commonly used for HCPCS level II; placeholder | Rarely appended; use payer-specific guidance |